nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.174	0.346	CbGbCtD
Midodrine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.174	0.346	CbGbCtD
Midodrine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.155	0.308	CbGbCtD
Midodrine—Vasodilation procedure—Salbutamol—chronic obstructive pulmonary disease	0.00479	0.0106	CcSEcCtD
Midodrine—Vasodilation—Salbutamol—chronic obstructive pulmonary disease	0.00479	0.0106	CcSEcCtD
Midodrine—Melatonin—MPO—chronic obstructive pulmonary disease	0.00474	0.316	CrCbGaD
Midodrine—Agomelatine—CYP1A2—chronic obstructive pulmonary disease	0.00468	0.312	CrCbGaD
Midodrine—Hepatobiliary disease—Roflumilast—chronic obstructive pulmonary disease	0.00464	0.0103	CcSEcCtD
Midodrine—Cramps of lower extremities—Formoterol—chronic obstructive pulmonary disease	0.00409	0.00904	CcSEcCtD
Midodrine—Cramps of lower extremities—Arformoterol—chronic obstructive pulmonary disease	0.00409	0.00904	CcSEcCtD
Midodrine—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00409	0.00904	CcSEcCtD
Midodrine—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.00406	0.00896	CcSEcCtD
Midodrine—Urinary retention—Aminophylline—chronic obstructive pulmonary disease	0.00404	0.00893	CcSEcCtD
Midodrine—Cramps of lower extremities—Salbutamol—chronic obstructive pulmonary disease	0.00386	0.00854	CcSEcCtD
Midodrine—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.00386	0.00853	CcSEcCtD
Midodrine—Urinary retention—Tiotropium—chronic obstructive pulmonary disease	0.00381	0.00842	CcSEcCtD
Midodrine—Tension—Roflumilast—chronic obstructive pulmonary disease	0.00377	0.00832	CcSEcCtD
Midodrine—Sleep disorder—Formoterol—chronic obstructive pulmonary disease	0.00374	0.00825	CcSEcCtD
Midodrine—Sleep disorder—Arformoterol—chronic obstructive pulmonary disease	0.00374	0.00825	CcSEcCtD
Midodrine—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.00373	0.00823	CcSEcCtD
Midodrine—Back pain—Roflumilast—chronic obstructive pulmonary disease	0.00371	0.0082	CcSEcCtD
Midodrine—Muscle spasms—Roflumilast—chronic obstructive pulmonary disease	0.00369	0.00815	CcSEcCtD
Midodrine—Dry skin—Tiotropium—chronic obstructive pulmonary disease	0.00367	0.00811	CcSEcCtD
Midodrine—Sleep disorder—Montelukast—chronic obstructive pulmonary disease	0.00366	0.00808	CcSEcCtD
Midodrine—Anxiety—Roflumilast—chronic obstructive pulmonary disease	0.00326	0.00719	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00324	0.00717	CcSEcCtD
Midodrine—Dysuria—Tiotropium—chronic obstructive pulmonary disease	0.00324	0.00716	CcSEcCtD
Midodrine—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00307	0.00679	CcSEcCtD
Midodrine—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.00304	0.00672	CcSEcCtD
Midodrine—Irritability—Montelukast—chronic obstructive pulmonary disease	0.00302	0.00668	CcSEcCtD
Midodrine—Stomatitis—Tiotropium—chronic obstructive pulmonary disease	0.00301	0.00665	CcSEcCtD
Midodrine—Dry skin—Formoterol—chronic obstructive pulmonary disease	0.00296	0.00655	CcSEcCtD
Midodrine—Dry skin—Arformoterol—chronic obstructive pulmonary disease	0.00296	0.00655	CcSEcCtD
Midodrine—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.00291	0.00644	CcSEcCtD
Midodrine—Melatonin—CYP1A1—chronic obstructive pulmonary disease	0.00284	0.189	CrCbGaD
Midodrine—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.00283	0.00626	CcSEcCtD
Midodrine—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.00276	0.00609	CcSEcCtD
Midodrine—Melatonin—CYP1A2—chronic obstructive pulmonary disease	0.00274	0.183	CrCbGaD
Midodrine—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.00274	0.00605	CcSEcCtD
Midodrine—Flushing—Aminophylline—chronic obstructive pulmonary disease	0.00273	0.00603	CcSEcCtD
Midodrine—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00272	0.006	CcSEcCtD
Midodrine—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.0027	0.00597	CcSEcCtD
Midodrine—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00258	0.0057	CcSEcCtD
Midodrine—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00256	0.00566	CcSEcCtD
Midodrine—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.00251	0.00556	CcSEcCtD
Midodrine—Tension—Aminophylline—chronic obstructive pulmonary disease	0.00251	0.00555	CcSEcCtD
Midodrine—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.00249	0.00549	CcSEcCtD
Midodrine—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00248	0.00547	CcSEcCtD
Midodrine—Dysuria—Salbutamol—chronic obstructive pulmonary disease	0.00247	0.00545	CcSEcCtD
Midodrine—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.00243	0.00537	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.00242	0.00535	CcSEcCtD
Midodrine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.00235	0.0052	CcSEcCtD
Midodrine—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.00233	0.00516	CcSEcCtD
Midodrine—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.00231	0.0051	CcSEcCtD
Midodrine—Stomatitis—Salbutamol—chronic obstructive pulmonary disease	0.00229	0.00507	CcSEcCtD
Midodrine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00225	0.00496	CcSEcCtD
Midodrine—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00221	0.00488	CcSEcCtD
Midodrine—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00221	0.00488	CcSEcCtD
Midodrine—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00219	0.00485	CcSEcCtD
Midodrine—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00219	0.00485	CcSEcCtD
Midodrine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.00217	0.0048	CcSEcCtD
Midodrine—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00216	0.00478	CcSEcCtD
Midodrine—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00215	0.00475	CcSEcCtD
Midodrine—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00209	0.00461	CcSEcCtD
Midodrine—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.00208	0.0046	CcSEcCtD
Midodrine—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.00208	0.00459	CcSEcCtD
Midodrine—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.00208	0.00459	CcSEcCtD
Midodrine—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.00207	0.00458	CcSEcCtD
Midodrine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00207	0.00458	CcSEcCtD
Midodrine—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00207	0.00458	CcSEcCtD
Midodrine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00205	0.00452	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00204	0.00451	CcSEcCtD
Midodrine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00204	0.0045	CcSEcCtD
Midodrine—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.00203	0.00449	CcSEcCtD
Midodrine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00201	0.00444	CcSEcCtD
Midodrine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00197	0.00436	CcSEcCtD
Midodrine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00197	0.00436	CcSEcCtD
Midodrine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00196	0.00433	CcSEcCtD
Midodrine—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00196	0.00433	CcSEcCtD
Midodrine—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.00196	0.00433	CcSEcCtD
Midodrine—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00196	0.00433	CcSEcCtD
Midodrine—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00196	0.00433	CcSEcCtD
Midodrine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00193	0.00427	CcSEcCtD
Midodrine—ADRA1D—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.00193	0.0637	CbGpPWpGaD
Midodrine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00192	0.00425	CcSEcCtD
Midodrine—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00192	0.00424	CcSEcCtD
Midodrine—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00192	0.00423	CcSEcCtD
Midodrine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00191	0.00423	CcSEcCtD
Midodrine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.00191	0.00422	CcSEcCtD
Midodrine—Tension—Formoterol—chronic obstructive pulmonary disease	0.00191	0.00422	CcSEcCtD
Midodrine—Chills—Salbutamol—chronic obstructive pulmonary disease	0.0019	0.00419	CcSEcCtD
Midodrine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.00189	0.00418	CcSEcCtD
Midodrine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.00189	0.00418	CcSEcCtD
Midodrine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00189	0.00417	CcSEcCtD
Midodrine—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.00188	0.00416	CcSEcCtD
Midodrine—Back pain—Formoterol—chronic obstructive pulmonary disease	0.00188	0.00416	CcSEcCtD
Midodrine—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.00187	0.00414	CcSEcCtD
Midodrine—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.00187	0.00414	CcSEcCtD
Midodrine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00186	0.00411	CcSEcCtD
Midodrine—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00185	0.00409	CcSEcCtD
Midodrine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00184	0.00406	CcSEcCtD
Midodrine—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00183	0.00405	CcSEcCtD
Midodrine—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00181	0.004	CcSEcCtD
Midodrine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.0018	0.00399	CcSEcCtD
Midodrine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00179	0.00395	CcSEcCtD
Midodrine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00179	0.00395	CcSEcCtD
Midodrine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00179	0.00395	CcSEcCtD
Midodrine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00178	0.00394	CcSEcCtD
Midodrine—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00178	0.00393	CcSEcCtD
Midodrine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.00177	0.00391	CcSEcCtD
Midodrine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.00177	0.00391	CcSEcCtD
Midodrine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00175	0.00387	CcSEcCtD
Midodrine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00173	0.00383	CcSEcCtD
Midodrine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00171	0.00377	CcSEcCtD
Midodrine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.0017	0.00376	CcSEcCtD
Midodrine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00169	0.00373	CcSEcCtD
Midodrine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00168	0.00371	CcSEcCtD
Midodrine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00168	0.00371	CcSEcCtD
Midodrine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.00165	0.00365	CcSEcCtD
Midodrine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.00165	0.00365	CcSEcCtD
Midodrine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00165	0.00365	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00165	0.00364	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00165	0.00364	CcSEcCtD
Midodrine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00162	0.00358	CcSEcCtD
Midodrine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00162	0.00358	CcSEcCtD
Midodrine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00162	0.00358	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00161	0.00356	CcSEcCtD
Midodrine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00161	0.00356	CcSEcCtD
Midodrine—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00161	0.00355	CcSEcCtD
Midodrine—ADRA1B—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.0016	0.0529	CbGpPWpGaD
Midodrine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00159	0.00351	CcSEcCtD
Midodrine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00156	0.00345	CcSEcCtD
Midodrine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00156	0.00344	CcSEcCtD
Midodrine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00156	0.00344	CcSEcCtD
Midodrine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00156	0.00344	CcSEcCtD
Midodrine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00155	0.00343	CcSEcCtD
Midodrine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00155	0.00343	CcSEcCtD
Midodrine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00154	0.00341	CcSEcCtD
Midodrine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00154	0.00341	CcSEcCtD
Midodrine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00153	0.00338	CcSEcCtD
Midodrine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00153	0.00337	CcSEcCtD
Midodrine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00151	0.00334	CcSEcCtD
Midodrine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00148	0.00326	CcSEcCtD
Midodrine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00147	0.00325	CcSEcCtD
Midodrine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00146	0.00324	CcSEcCtD
Midodrine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00146	0.00322	CcSEcCtD
Midodrine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00144	0.00318	CcSEcCtD
Midodrine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00144	0.00318	CcSEcCtD
Midodrine—ADRA1A—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.00142	0.047	CbGpPWpGaD
Midodrine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00142	0.00313	CcSEcCtD
Midodrine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00142	0.00313	CcSEcCtD
Midodrine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00141	0.00312	CcSEcCtD
Midodrine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00141	0.00312	CcSEcCtD
Midodrine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00141	0.00311	CcSEcCtD
Midodrine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.0014	0.00309	CcSEcCtD
Midodrine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.0014	0.00309	CcSEcCtD
Midodrine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.0014	0.00309	CcSEcCtD
Midodrine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00139	0.00308	CcSEcCtD
Midodrine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00138	0.00306	CcSEcCtD
Midodrine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00138	0.00305	CcSEcCtD
Midodrine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00137	0.00303	CcSEcCtD
Midodrine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00137	0.00303	CcSEcCtD
Midodrine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00137	0.00303	CcSEcCtD
Midodrine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00136	0.003	CcSEcCtD
Midodrine—Pain—Formoterol—chronic obstructive pulmonary disease	0.00136	0.003	CcSEcCtD
Midodrine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00136	0.003	CcSEcCtD
Midodrine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00135	0.00298	CcSEcCtD
Midodrine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00134	0.00297	CcSEcCtD
Midodrine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00296	CcSEcCtD
Midodrine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00133	0.00295	CcSEcCtD
Midodrine—Pain—Montelukast—chronic obstructive pulmonary disease	0.00133	0.00294	CcSEcCtD
Midodrine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.00132	0.00292	CcSEcCtD
Midodrine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00132	0.00291	CcSEcCtD
Midodrine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00132	0.00291	CcSEcCtD
Midodrine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00131	0.00289	CcSEcCtD
Midodrine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00131	0.00289	CcSEcCtD
Midodrine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.00289	CcSEcCtD
Midodrine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.0013	0.00288	CcSEcCtD
Midodrine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.0013	0.00287	CcSEcCtD
Midodrine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.0013	0.00287	CcSEcCtD
Midodrine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.0013	0.00286	CcSEcCtD
Midodrine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00128	0.00284	CcSEcCtD
Midodrine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00127	0.00281	CcSEcCtD
Midodrine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00126	0.00278	CcSEcCtD
Midodrine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00126	0.00278	CcSEcCtD
Midodrine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00124	0.00274	CcSEcCtD
Midodrine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00124	0.00274	CcSEcCtD
Midodrine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00124	0.00274	CcSEcCtD
Midodrine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00124	0.00273	CcSEcCtD
Midodrine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00123	0.00273	CcSEcCtD
Midodrine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00123	0.00273	CcSEcCtD
Midodrine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00272	CcSEcCtD
Midodrine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00123	0.00271	CcSEcCtD
Midodrine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00121	0.00268	CcSEcCtD
Midodrine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.00262	CcSEcCtD
Midodrine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00117	0.00258	CcSEcCtD
Midodrine—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.00117	0.00258	CcSEcCtD
Midodrine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00252	CcSEcCtD
Midodrine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00252	CcSEcCtD
Midodrine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00112	0.00248	CcSEcCtD
Midodrine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00112	0.00248	CcSEcCtD
Midodrine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00112	0.00247	CcSEcCtD
Midodrine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.0011	0.00243	CcSEcCtD
Midodrine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00238	CcSEcCtD
Midodrine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00106	0.00235	CcSEcCtD
Midodrine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00105	0.00232	CcSEcCtD
Midodrine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.00232	CcSEcCtD
Midodrine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00103	0.00227	CcSEcCtD
Midodrine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.001	0.00221	CcSEcCtD
Midodrine—Rash—Formoterol—chronic obstructive pulmonary disease	0.001	0.00221	CcSEcCtD
Midodrine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.001	0.00221	CcSEcCtD
Midodrine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.001	0.00221	CcSEcCtD
Midodrine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000996	0.0022	CcSEcCtD
Midodrine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000996	0.0022	CcSEcCtD
Midodrine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000992	0.00219	CcSEcCtD
Midodrine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000982	0.00217	CcSEcCtD
Midodrine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000981	0.00217	CcSEcCtD
Midodrine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000975	0.00215	CcSEcCtD
Midodrine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000946	0.00209	CcSEcCtD
Midodrine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000945	0.00209	CcSEcCtD
Midodrine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000944	0.00209	CcSEcCtD
Midodrine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000944	0.00209	CcSEcCtD
Midodrine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00094	0.00208	CcSEcCtD
Midodrine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000925	0.00204	CcSEcCtD
Midodrine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000911	0.00201	CcSEcCtD
Midodrine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000896	0.00198	CcSEcCtD
Midodrine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000891	0.00197	CcSEcCtD
Midodrine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00084	0.00186	CcSEcCtD
Midodrine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000817	0.00181	CcSEcCtD
Midodrine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000799	0.00176	CcSEcCtD
Midodrine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000779	0.00172	CcSEcCtD
Midodrine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000773	0.00171	CcSEcCtD
Midodrine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000771	0.0017	CcSEcCtD
Midodrine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000736	0.00163	CcSEcCtD
Midodrine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000709	0.00157	CcSEcCtD
Midodrine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000704	0.00156	CcSEcCtD
Midodrine—ADRA1D—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000682	0.0225	CbGpPWpGaD
Midodrine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000662	0.00146	CcSEcCtD
Midodrine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.00065	0.00144	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000648	0.00143	CcSEcCtD
Midodrine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000626	0.0207	CbGpPWpGaD
Midodrine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000613	0.00136	CcSEcCtD
Midodrine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00061	0.00135	CcSEcCtD
Midodrine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000608	0.00134	CcSEcCtD
Midodrine—ADRA1D—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000573	0.0189	CbGpPWpGaD
Midodrine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000569	0.00126	CcSEcCtD
Midodrine—ADRA1B—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000566	0.0187	CbGpPWpGaD
Midodrine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000566	0.00125	CcSEcCtD
Midodrine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000562	0.00124	CcSEcCtD
Midodrine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000551	0.00122	CcSEcCtD
Midodrine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000543	0.0012	CcSEcCtD
Midodrine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000542	0.0012	CcSEcCtD
Midodrine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000539	0.00119	CcSEcCtD
Midodrine—ADRA1D—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000533	0.0176	CbGpPWpGaD
Midodrine—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000523	0.0173	CbGpPWpGaD
Midodrine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000515	0.00114	CcSEcCtD
Midodrine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000511	0.00113	CcSEcCtD
Midodrine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000511	0.00113	CcSEcCtD
Midodrine—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000503	0.0166	CbGpPWpGaD
Midodrine—ADRA1A—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000503	0.0166	CbGpPWpGaD
Midodrine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000494	0.00109	CcSEcCtD
Midodrine—ADRA1D—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	0.000483	0.016	CbGpPWpGaD
Midodrine—ADRA1B—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000476	0.0157	CbGpPWpGaD
Midodrine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000455	0.015	CbGpPWpGaD
Midodrine—SLC15A1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00045	0.0149	CbGpPWpGaD
Midodrine—ADRA1A—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	0.000449	0.0148	CbGpPWpGaD
Midodrine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000449	0.000992	CcSEcCtD
Midodrine—ADRA1D—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000448	0.0148	CbGpPWpGaD
Midodrine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000443	0.000978	CcSEcCtD
Midodrine—ADRA1B—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000442	0.0146	CbGpPWpGaD
Midodrine—ADRA1A—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000422	0.014	CbGpPWpGaD
Midodrine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000414	0.000914	CcSEcCtD
Midodrine—SLC15A1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000401	0.0133	CbGpPWpGaD
Midodrine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000394	0.000871	CcSEcCtD
Midodrine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000394	0.000871	CcSEcCtD
Midodrine—ADRA1A—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000393	0.013	CbGpPWpGaD
Midodrine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000392	0.000866	CcSEcCtD
Midodrine—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000389	0.0129	CbGpPWpGaD
Midodrine—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00038	0.0126	CbGpPWpGaD
Midodrine—ADRA1B—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000372	0.0123	CbGpPWpGaD
Midodrine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000372	0.000821	CcSEcCtD
Midodrine—ADRA1B—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000367	0.0121	CbGpPWpGaD
Midodrine—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000366	0.0121	CbGpPWpGaD
Midodrine—ADRA1A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.00033	0.0109	CbGpPWpGaD
Midodrine—ADRA1A—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000326	0.0108	CbGpPWpGaD
Midodrine—ADRA1D—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	0.000303	0.01	CbGpPWpGaD
Midodrine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000302	0.00997	CbGpPWpGaD
Midodrine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000283	0.00934	CbGpPWpGaD
Midodrine—ADRA1A—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	0.000274	0.00904	CbGpPWpGaD
Midodrine—ADRA1D—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	0.000237	0.00782	CbGpPWpGaD
Midodrine—ADRA1B—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000228	0.00753	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000222	0.00735	CbGpPWpGaD
Midodrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000217	0.00719	CbGpPWpGaD
Midodrine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000215	0.00709	CbGpPWpGaD
Midodrine—ADRA1D—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00021	0.00693	CbGpPWpGaD
Midodrine—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000204	0.00675	CbGpPWpGaD
Midodrine—ADRA1A—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000202	0.00669	CbGpPWpGaD
Midodrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00018	0.00594	CbGpPWpGaD
Midodrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000176	0.00582	CbGpPWpGaD
Midodrine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000174	0.00575	CbGpPWpGaD
Midodrine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000169	0.0056	CbGpPWpGaD
Midodrine—ADRA1B—LPA receptor mediated events—CXCL8—chronic obstructive pulmonary disease	0.000161	0.00532	CbGpPWpGaD
Midodrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000158	0.00522	CbGpPWpGaD
Midodrine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000156	0.00515	CbGpPWpGaD
Midodrine—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000155	0.00511	CbGpPWpGaD
Midodrine—ADRA1D—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000152	0.00503	CbGpPWpGaD
Midodrine—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.00015	0.00497	CbGpPWpGaD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000149	0.00493	CbGpPWpGaD
Midodrine—ADRA1B—LPA receptor mediated events—MMP9—chronic obstructive pulmonary disease	0.000145	0.00481	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000137	0.00452	CbGpPWpGaD
Midodrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000136	0.0045	CbGpPWpGaD
Midodrine—ADRA1D—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000133	0.0044	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000132	0.00438	CbGpPWpGaD
Midodrine—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000132	0.00435	CbGpPWpGaD
Midodrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00423	CbGpPWpGaD
Midodrine—ADRA1B—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000126	0.00417	CbGpPWpGaD
Midodrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000119	0.00393	CbGpPWpGaD
Midodrine—ADRA1B—LPA receptor mediated events—EGFR—chronic obstructive pulmonary disease	0.000118	0.00389	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000114	0.00375	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000113	0.00373	CbGpPWpGaD
Midodrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000113	0.00373	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000113	0.00372	CbGpPWpGaD
Midodrine—ADRA1A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000112	0.00371	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000112	0.0037	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000111	0.00368	CbGpPWpGaD
Midodrine—ADRA1B—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.00011	0.00365	CbGpPWpGaD
Midodrine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000109	0.00361	CbGpPWpGaD
Midodrine—SLC15A1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000104	0.00345	CbGpPWpGaD
Midodrine—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000103	0.0034	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000101	0.00333	CbGpPWpGaD
Midodrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000101	0.00333	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.0001	0.00331	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	9.88e-05	0.00326	CbGpPWpGaD
Midodrine—ADRA1A—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	9.81e-05	0.00324	CbGpPWpGaD
Midodrine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	9.7e-05	0.00321	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	9.59e-05	0.00317	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.36e-05	0.00309	CbGpPWpGaD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	9.35e-05	0.00309	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	9.3e-05	0.00307	CbGpPWpGaD
Midodrine—ADRA1B—AMPK Signaling—TP53—chronic obstructive pulmonary disease	9.3e-05	0.00307	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.23e-05	0.00305	CbGpPWpGaD
Midodrine—SLC15A1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.82e-05	0.00292	CbGpPWpGaD
Midodrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	8.81e-05	0.00291	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	8.77e-05	0.0029	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	8.71e-05	0.00288	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	8.58e-05	0.00284	CbGpPWpGaD
Midodrine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.54e-05	0.00282	CbGpPWpGaD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	8.36e-05	0.00276	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	8.31e-05	0.00275	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.26e-05	0.00273	CbGpPWpGaD
Midodrine—ADRA1A—AMPK Signaling—TP53—chronic obstructive pulmonary disease	8.26e-05	0.00273	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.96e-05	0.00263	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.81e-05	0.00258	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	7.73e-05	0.00256	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.7e-05	0.00255	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	7.67e-05	0.00254	CbGpPWpGaD
Midodrine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	7.58e-05	0.00251	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	7.43e-05	0.00245	CbGpPWpGaD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	7.31e-05	0.00242	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	7.23e-05	0.00239	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.17e-05	0.00237	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	7.12e-05	0.00235	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.08e-05	0.00234	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.07e-05	0.00234	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.02e-05	0.00232	CbGpPWpGaD
Midodrine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.8e-05	0.00225	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	6.79e-05	0.00224	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	6.71e-05	0.00222	CbGpPWpGaD
Midodrine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.71e-05	0.00222	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	6.5e-05	0.00215	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.42e-05	0.00212	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.42e-05	0.00212	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.37e-05	0.0021	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	6.33e-05	0.00209	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.83e-05	0.00193	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.7e-05	0.00188	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.65e-05	0.00187	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.64e-05	0.00186	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.57e-05	0.00184	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	5.47e-05	0.00181	CbGpPWpGaD
Midodrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.44e-05	0.0018	CbGpPWpGaD
Midodrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	5.37e-05	0.00178	CbGpPWpGaD
Midodrine—SLC15A1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.3e-05	0.00175	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.18e-05	0.00171	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.15e-05	0.0017	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.01e-05	0.00165	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.95e-05	0.00164	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.85e-05	0.0016	CbGpPWpGaD
Midodrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.52e-05	0.00149	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	4.46e-05	0.00147	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.4e-05	0.00146	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.33e-05	0.00143	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.27e-05	0.00141	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.15e-05	0.00137	CbGpPWpGaD
Midodrine—ADRA1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.15e-05	0.00137	CbGpPWpGaD
Midodrine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	4.13e-05	0.00136	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.03e-05	0.00133	CbGpPWpGaD
Midodrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.01e-05	0.00133	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	3.96e-05	0.00131	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.94e-05	0.0013	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.79e-05	0.00125	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.79e-05	0.00125	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.66e-05	0.00121	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.62e-05	0.0012	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.6e-05	0.00119	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.58e-05	0.00118	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	3.53e-05	0.00117	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.44e-05	0.00114	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.44e-05	0.00114	CbGpPWpGaD
Midodrine—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.44e-05	0.00114	CbGpPWpGaD
Midodrine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	3.43e-05	0.00113	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.28e-05	0.00108	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.27e-05	0.00108	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.25e-05	0.00107	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.2e-05	0.00106	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.15e-05	0.00104	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.06e-05	0.00101	CbGpPWpGaD
Midodrine—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.06e-05	0.00101	CbGpPWpGaD
Midodrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	3.04e-05	0.00101	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.03e-05	0.001	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.9e-05	0.000959	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.86e-05	0.000945	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.82e-05	0.000932	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.8e-05	0.000924	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.6e-05	0.00086	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.54e-05	0.000839	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.52e-05	0.000832	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.34e-05	0.000774	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.34e-05	0.000774	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.33e-05	0.000769	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.24e-05	0.000739	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.16e-05	0.000714	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.13e-05	0.000703	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.11e-05	0.000699	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.08e-05	0.000687	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.03e-05	0.000672	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.94e-05	0.000643	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.93e-05	0.000638	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.93e-05	0.000637	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.92e-05	0.000634	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.9e-05	0.000629	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.89e-05	0.000625	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.77e-05	0.000584	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.75e-05	0.00058	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.74e-05	0.000574	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.73e-05	0.000571	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.71e-05	0.000567	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.69e-05	0.000558	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.6e-05	0.000529	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.57e-05	0.000519	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.57e-05	0.000518	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.56e-05	0.000515	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.55e-05	0.000514	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.5e-05	0.000496	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.48e-05	0.000491	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.42e-05	0.000468	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.39e-05	0.000461	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.34e-05	0.000441	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.32e-05	0.000435	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.29e-05	0.000427	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000415	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.23e-05	0.000407	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.23e-05	0.000406	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.19e-05	0.000395	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.18e-05	0.000389	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.16e-05	0.000384	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.15e-05	0.000379	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.14e-05	0.000376	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.09e-05	0.000362	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.04e-05	0.000345	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.04e-05	0.000345	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.02e-05	0.000337	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.92e-06	0.000328	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.43e-06	0.000312	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.37e-06	0.00031	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.26e-06	0.000306	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.19e-06	0.000304	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.81e-06	0.000291	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.47e-06	0.00028	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.38e-06	0.000277	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	7.91e-06	0.000261	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.78e-06	0.000257	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.71e-06	0.000255	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.62e-06	0.000252	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.56e-06	0.00025	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.52e-06	0.000249	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.06e-06	0.000233	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.91e-06	0.000228	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.77e-06	0.000224	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.4e-06	0.000212	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.86e-06	0.000194	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.69e-06	0.000188	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.2e-06	0.000172	CbGpPWpGaD
